A new study has identified a potential new target for treating triple-negative breast cancer, one of the most aggressive forms of breast cancer, which still has very few therapeutic options available.

New results from a clinical trial show that existing drugs can successfully kill dormant breast cancer cells, thereby reducing lifetime risk of recurrence.

Thousands of survivors, health care professionals, and community organizers are rallying this Breast Cancer Awareness season ...

A groundbreaking study conducted by researchers from McGill University, the Lady Davis Institute for Medical Research (LDI) ...

Women under 40 are nearly 40% more likely to die from breast cancer than women over 40 because they are more likely to have aggressive forms of the disease.

This should not have to be a fight,” Van Hollen said at a rally by the American Cancer Society. “It is not a partisan issue.” ...

April 1, 2025 – Advances in breast cancer screening and treatment have saved a lot of lives over the past few decades – for some groups more than others. Overall, the number of Americans dying of ...

More cancer patients will soon be able to enroll in a groundbreaking Phase 2 clinical trial of a therapeutic breast cancer ...

Angeletha Smith, a cancer survivor, holds a picture of her mother who died from cancer last year. PHOTO COURTESY OF SYLVESTER COMPREHENSIVE CANCER CENTER AT ...

NIH award of $2.25M funds preclinical studies that will advance Targefrin toward clinical trials for pancreatic cancer ...

Risk factors for developing breast cancer include being female, increasing age, being overweight, alcohol consumption and ...